Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil

Loss, Jiseh Fagundes; Santos, Pedro Paulo Albino dos; Leone, Luciane Pons Di; Brunetto, Algemir Lunardi

doi:10.1002/pbc.10375

Cited by 15 publications

(10 citation statements)

References 12 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, nine patients (26%) were hospitalized for management of fever and neutropenia within the study period. This rate is comparable to the reported rate in the literature with respect to aggressive ALL and solid tumor protocols 13–16, suggesting that there is no increased risk to patients in this setting. Only one patient (3%) had definitive evidence of microbial infection.…”

Section: Discussionsupporting

confidence: 82%

Low prevalence of complications in severe neutropenic children with cancer in the unprotected environment of an overnight camp

Tabori

Jones

Malkin

2006

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 82%

Low prevalence of complications in severe neutropenic children with cancer in the unprotected environment of an overnight camp

Tabori

Jones

Malkin

2006

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…The toxicity in this trial was as expected and was similar to that of other regimens used for the treatment of pediatric solid tumors at diagnosis or after relapse. [18][19][20] The response rate of 31.5% for VI was modest, 6 particularly in comparison with the 70% response rate seen in an upfront phase 2 window trial of previously untreated patients with metastatic RMS. 21 After the investigation of the VI phase 2 window in the first-relapse setting for RMS, the combination was investigated with alternating cycles of VAC chemotherapy in newly diagnosed patients with intermediate-risk RMS by COG (ARST0531), but it failed to improve outcomes.…”

Section: Discussionmentioning

confidence: 88%

Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group

Mascarenhas

Lyden

Breitfeld

et al. 2019

Cancer

View full text Add to dashboard Cite

Background The purpose of this study was to evaluate risk and response–based multi‐agent therapy for patients with rhabdomyosarcoma (RMS) at first relapse. Methods Patients with RMS and measurable disease at first relapse with unfavorable‐risk (UR) features were randomized to a 6‐week phase 2 window with 1 of 2 treatment schedules of irinotecan with vincristine (VI) (previously reported). Those with at least a partial response to VI continued to receive 44 weeks of multi‐agent chemotherapy including the assigned VI regimen. UR patients who did not have measurable disease at study entry, did not have a radiographic response after the VI window, or declined VI window therapy received 31 weeks of multi‐agent chemotherapy including tirapazamine (TPZ) at weeks 1, 4, 10, 19, and 28. Favorable‐risk (FR) patients received 31 weeks of the same multi‐agent chemotherapy without VI and TPZ. Results One hundred thirty‐six eligible patients were enrolled. For 61 patients not responding to VI, the 3‐year failure‐free survival (FFS) and overall survival (OS) rates were 17% (95% confidence interval [CI], 8%‐29%) and 24% (13%‐37%), respectively. For 30 UR patients not treated with VI, the 3‐year FFS and OS rates were 21% (8%‐37%) and 39% (20%‐57%), respectively. FR patients had 3‐year FFS and OS rates of 79% (47%‐93%) and 84% (50%‐96%), respectively. There were no unexpected toxicities. Conclusions Patients with UR RMS at first relapse or disease progression have a poor prognosis when they are treated with this multi‐agent therapy, whereas FR patients have a higher chance of being cured with second‐line therapy.

show abstract

“…), the tumor markers became to be normal after CBT, with no symptoms. In patient 2, the relapse site was cranial bone and bone marrow, similar to the first diagnosis, and this patient underwent conventional chemotherapy including ICE or IREC (irinotecan, etoposide, carboplatin) . Patients 3 and 4 maintained CR after CBT.…”

Section: Resultsmentioning

confidence: 99%

“…All patients received 5‐6 cycles of conventional chemotherapy treatments followed by APBSCT with high‐dose chemotherapy (busulfan, 4.8 mg/kg; melphalan, 140 mg/m 2 ). Conventional chemotherapy included A1 (Cyclophosphamide, Vincristine, Pirarubicin, Cisplatin), A3 (Cyclophosphamide, Vincristine, Pirarubicin, Cisplatin), and ICE (Ifosfamide, Carboplatin, Etoposide) . Primary surgical resection and radiation therapy (primary tumor, 30.6 Gy; lymph metastasis, 19.8 Gy) were conducted and followed by KIR‐CBT with RIC.…”

Section: Methodsmentioning

confidence: 99%

Killer‐cell immunoglobulin‐like receptor ligand mismatch cord blood transplantation in high‐risk neuroblastoma

Matsuno

Toyama

Akiyama

et al. 2019

Pediatrics International

View full text Add to dashboard Cite

Background The prognosis of high‐risk neuroblastoma stage 4 with bone marrow metastasis, MYCN amplified, or refractory neuroblastoma is poor. To date, no standard treatment has been established. In four selected cases, we challenged the killer‐cell immunoglobulin‐like receptor ligand mismatch cord blood transplantation in graft‐versus‐host disease (GVHD) with reduced‐intensity conditioning. Methods Prior to this study, conventional chemotherapy, autologous peripheral blood stem cell transplantation with high‐dose chemotherapy (busulfan and melphalan), surgery and radiation therapy were completed in every case. The status before cord blood transplantation in two cases was not complete remission (CR) and in the others it was CR. The primary site was the mediastinum, two adrenal glands and a retroperitoneum, respectively. Three patients had bone and bone marrow metastasis and one had MYCN amplification. In all cases, international neuroblastoma pathology classification was unfavorable histology. All patients were >2 years of age. Results Relapse occurred only in one patient 17 months after the last transplantation, and the other three patients maintained disease‐free survival for 74, 36, and 24 months, respectively. In one case of relapse the disease could be controlled by conventional chemotherapy. Except one, all patients had no severe complications, such as acute or chronic GVHD. One patient had gastric antral vascular ectasia and hemorrhagic cystitis. Conclusion This strategy might be feasible and should be investigated for efficacy in the future. No definite conclusion can be made, however, due to the very small number of patients. Further prospective studies are required to determine its efficacy.

show abstract

Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil

Cited by 15 publications

References 12 publications

Low prevalence of complications in severe neutropenic children with cancer in the unprotected environment of an overnight camp

Low prevalence of complications in severe neutropenic children with cancer in the unprotected environment of an overnight camp

Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group

Killer‐cell immunoglobulin‐like receptor ligand mismatch cord blood transplantation in high‐risk neuroblastoma

Contact Info

Product

Resources

About